42 results on '"Andreasen, P.A."'
Search Results
2. Oestradiol and basic fibroblast growth factor stimulate expression of very low density lipoprotein receptor and plasminogen activator inhibitor-1 in breast carcinoma cell lines
3. CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines
4. Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis
5. Mutational analysis of plasminogen activator inhibitor-1. Interactions of a-helix F and its neighbouring structural elements regulates the activity and the rate of latency transition
6. Mapping of the epitope for a monoclonal anti-plasminogen activator inhibitor-1 antibody protecting against inactivating agents
7. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor-1: Roles of the reactive centre loop, the shutter region, the flexible joint region, and the small serpin fragment
8. The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand
9. The role of β-strand 5A residues of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin
10. Importance of the amino acid composition of the shutter region of plasminogen activator inhibitor-1 for its transition to latent and substrate forms
11. Localization of epitopes for monoclonal anti-urokinase-type plasminogen activator antibodies. Relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme
12. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1. Implications for antibody-mediated PAI-1 neutralisation and vitronectin binding
13. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism
14. Alpha-2 macroglobulin receptor/LDL receptor-related protein (LRP)-dependent internalization of the urokinase receptor
15. Plasminogen activators in bovine milk during mastitis, an inflammatory disease
16. Binding of plasminogen and tissue-type plasminogen activator to dimeric α s2-casein accelerates plasmin generation
17. Aqueous two-phase partition studies of the glucocorticoid receptor activation and pH-dependent changes of rat liver glucocorticoid-receptor complex in partly purified preparations
18. Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator
19. Occurrence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumour vessel blood from patients with ovarian carcinoma
20. Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies
21. Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats
22. Plasminogen Activators, Tissue Degradation, and Cancer
23. Dimeric αs2-casein, a novel matrix for tissue-type plasminogen activator catalyzed plasminogen activation
24. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
25. Proenzyme to urokinase-type plasminogen activator in the mouse in vivo
26. Plasminogen activator inhibitor type-1 : reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing
27. 171 Mechanisms of neutralization of the inhibitory activity of PAI-1 by monoclonal antibodies directed against the β-strand 1A/α-helix F region
28. 164 Conformational differences between free and complexed forms of uPA and PAI-1, as probed by proteolytic susceptibility
29. 163 Vitronectin induces conformational changes of the hinge of the reactive centre loop and of β-strand 5A and affects inhibitor-to-substrate transition of PAI-1
30. 36 Plasminogen activator inhibitor type-1 inhibits integrin- and vitronectin-dependent cell migration
31. 648 Prognostic significance of UPA and PAI-1 in relation to other prognosticators for the clinical outcome of breast cancer
32. Transforming growth factor-beta induces incresed level of plasminogen activator inhibitor mRNA in human lung fibroblasts
33. The regulatory region of the human plasminogen activator inhibitor-type 1 (PAI-1) gene
34. Type-1 plasminogen activator inhibitor (PAI-1): Cell-specific expression and hormonal regulation in human cell lines
35. The phorbol ester, PMA, increases cellular levels of mRNA coding for plasminogen activator inhibitor type-1 (PAI-1) in human neoplastic cells
36. Inactive zymogen forms of plasminogen activators from human neoplastic cells
37. 316 Increased production of plasminogen activator inhibitor type-1 (PAI-1) in human neoplastic cell lines exposed to tumor-promoting phorbol esters
38. 42 Type-1 plasminogen activator inhibitor (PAI-1): Cell-specific expression and hormonal regulation in human cell lines
39. Regulation of type-1 plasminogen activator inhibitor (PAI-1) gene expression in human cell lines
40. Tumor necrosis factor-alpha regulates urokinase-type plasminogen activator and its type-1 inhibitor in human neoplas71c cell lines
41. Urokinase-type plasminogen activator is increased during castration-induced involution of the rat ventral prostate
42. Transforming growth factor-β and glucocorticoid regulation of plasminogen activator inhibitor type-1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.